Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia 27-10-2025, 19:19

ML Tech’s Digital Asset Market Neutral Opportunities Fund Reaches Milestone of Six Months of Live Trading 24-04-2024, 21:00